These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19951181)

  • 1. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.
    Malik ZA; Hailpern SM; Burk RD
    Viral Immunol; 2009 Dec; 22(6):445-9. PubMed ID: 19951181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of seropositivity to human papillomavirus type 53: one of the most prevalent high risk-related cervical human papillomaviruses.
    Malik ZA; Hailpern SM; Burk RD
    Viral Immunol; 2008 Sep; 21(3):371-7. PubMed ID: 18681800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The known unknowns of HPV natural history.
    Gravitt PE
    J Clin Invest; 2011 Dec; 121(12):4593-9. PubMed ID: 22133884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
    Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
    J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
    [No Abstract]   [Full Text] [Related]  

  • 7. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.
    Studentsov YY; Ho GY; Marks MA; Bierman R; Burk RD
    J Clin Microbiol; 2003 Jul; 41(7):2827-34. PubMed ID: 12843008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
    Jagu S; Kwak K; Schiller JT; Lowy DR; Kleanthous H; Kalnin K; Wang C; Wang HK; Chow LT; Huh WK; Jaganathan KS; Chivukula SV; Roden RB
    J Virol; 2013 Jun; 87(11):6127-36. PubMed ID: 23536682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
    Viscidi RP; Ahdieh-Grant L; Schneider MF; Clayman B; Massad LS; Anastos KM; Burk RD; Minkoff H; Palefsky J; Levine A; Strickler H
    J Infect Dis; 2003 Dec; 188(12):1834-44. PubMed ID: 14673762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
    Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
    J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.
    Nakagawa M; Viscidi R; Deshmukh I; Costa MD; Palefsky JM; Farhat S; Moscicki AB
    Clin Diagn Lab Immunol; 2002 Jul; 9(4):877-82. PubMed ID: 12093689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of human papillomavirus by specific nanobodies against major capsid protein L1.
    Minaeian S; Rahbarizadeh F; Zarkesh-Esfahani SH; Ahmadvand D; Broom OJ
    J Microbiol Biotechnol; 2012 May; 22(5):721-8. PubMed ID: 22561868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.
    Ermel AC; Shew ML; Weaver BA; Qadadri B; Denski C; Tu W; Tong Y; Fortenberry JD; Brown DR
    Sex Transm Infect; 2014 Feb; 90(1):64-9. PubMed ID: 24031030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
    Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
    Front Immunol; 2020; 11():606569. PubMed ID: 33343580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.
    Bywaters SM; Brendle SA; Biryukov J; Wang JW; Walston J; Milici J; Roden RB; Meyers C; Christensen ND
    Virology; 2018 Nov; 524():106-113. PubMed ID: 30170240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.